The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes

COMMENTED

Diabetes - GeneralType 2 Diabetes

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J Med.

Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S

doi: 10.1056/NEJMoa1800256.

Type 2 Diabetes

Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes

Diabet Med.

Sharif S, Visseren FLJ, Spiering W, de Jong PA, Bots ML, Westerink J; SMART study group

doi: 10.1111/dme.13954.

COMMENTED

Type 2 Diabetes

Association Between Blood Pressure Variability, Cardiovascular Disease And Mortality In Type 2 Diabetes: A Systematic Review And Meta-Analysis

Diabetes Obes Metab.

Chiriacò M, Pateras K, Virdis A, Charakida M, Kyriakopoulou D, Nannipieri M, Emdin M, Tsioufis C, Taddei S, Masi S, Georgiopoulos G

doi: 10.1111/dom.13828.

Diabetes - GeneralType 2 Diabetes

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Lancet Diabetes Endocrinol.

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A

doi: 10.1016/

COMMENTED

Diabetes - GeneralType 2 Diabetes

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Diabetologia.

Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A

doi: 10.1007/s00125-017-4323-2.

Diabetes - GeneralType 2 Diabetes

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Diabetologia.

Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B

doi: 10.1007/s00125-018-4644-9.

COMMENTED

Type 2 Diabetes

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Lancet Diabetes Endocrinol.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV

doi: 10.1016/S2213-8587(19)30249-9.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Diabetes Care.

Kaul S

doi: 10.2337/

COMMENTED

Type 2 Diabetes

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Diabetes Obes Metab.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V

doi: 10.1111/dom.

Related content

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes

Association Between Blood Pressure Variability, Cardiovascular Disease And Mortality In Type 2 Diabetes: A Systematic Review And Meta-Analysis

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis